On April 17, Regeneron (REGN) Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for EYLEA HD ...

Regeneron Pharmaceuticals has announced the U.S. FDA's acceptance for Priority Review of the supplemental Biologics License Application for EYLEA HD (aflibercept) Injection 8 mg, which, if ...

In this article, we are going to look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other biotech stocks. The biotechnology sector is gaining new momentum with better ...

BofA cuts Regeneron price target to $547, maintains Underperform rating. China’s new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for Matt Maley.

In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc (NASDAQ:REGN) stands against other stocks that Jim Cramer discusses. Jim Cramer in a recent program on CNBC ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other most profitable biotech stocks to buy right now. With improved market ...

In a report released on April 11, Salveen Richter from Goldman Sachs maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of $917.00. The company’s shares closed ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...